PhosImmune is an immunotherapy company that controls a growing library of phosphopeptide tumor targets (PTTs) that have been discovered by researchers at the Universities of Virginia (US) and Birmingham (UK).

PTTs are a unique class of novel tumor targets:

  • They are highly expressed on cancer cells with low/no expression on normal cells;
  • They are found on a wide number of cancer types;
  • They are derived from proteins involved in key pathways that underpin the development and maintenance of malignancy:
    • This reduces their propensity for down-regulation and escape from immunological or therapeutic attack.

Importantly, many PTTs have been discovered for which there is strong pre-existing memory T-cell immunity among healthy subjects but low/no immunity among cancer patients. This implies that reconstituting or redirecting an immune response to these targets will effect a renewed control over the disease.

PhosImmune has a proprietary PTT discovery methodology which allows for rapid identification and selection of PTTs for a number of immuno-oncology applications:

  • Monoclonal antibody therapy: naked antibodies, antibody-drug conjugates, bispecific
  • Chimeric antigen receptor-T cell (CAR-T) therapy;
  • TCR-based therapy: soluble TCRs or adoptive T-cell therapy.

PhosImmune will generate an internal pipeline of tumor-specific therapeutic candidates and in parallel will work with partner companies to maximise the exploitation of its technology towards addressing a wide range of cancer indications.